Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

Arthritis and Rheumatism

Volumn 42, Issue 7, 1999, Pages 1322-1328

  Weinblatt, Michael E ^a   Kremer, Joel M ^b   Coblyn, Jonathan S ^a   Maier, Agnes L ^a   Helfgott, Simon M ^a   Morrell, Martin ^b   Byrne, Vilma M ^b   Kaymakcian, Mari V ^b   Strand, Vibeke ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE; METHOTREXATE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HUMAN; HYPERTENSION; MALE; MOUTH ULCER; MYALGIA; NAUSEA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STOMATITIS;

ADULT; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; ASPARTATE AMINOTRANSFERASES; DIARRHEA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; LIVER; MALE; METHOTREXATE; MIDDLE AGED; NAUSEA; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 0033509841     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P     Document Type: Article

References (20)

1. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
2. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-9.
3. Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995;44:317-22.
4. WAF-1 pathways [abstract]. Arthritis Rheum 1997;40 Suppl 9:S177.
5. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;25 Suppl 53:S20-6.
6. Rückemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;273:21682-91.
7. Harris ED. Rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J Rheumatol 1996;23 Suppl 44:2-4.
8. Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
9. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard J. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322-8.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
12. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
13. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
14. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
15. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
16. Willkens RF, Urowitz MB, Stablein DM, McKendry RJR Jr, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:849-56.
17. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:259-69.
18. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334: 1287-91.
19. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
20. Van Ede AE, Laan RF, Blom HJ, de Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27: 277-92.